Vignesh Amal Arasu MD, Presenter: Nothing to Disclose

Warren J Gasper, Abstract Co-Author: Nothing to Disclose

Ryan Thomas Downey MD, Abstract Co-Author: Nothing to Disclose

Stefanie Weinstein MD, Abstract Co-Author: Nothing to Disclose

Rizwan Aslam MBBCh, Abstract Co-Author: Research support, Bayer AG

Thomas A. Hope MD, Abstract Co-Author: Speaker, Guerbet SA Research Grant, General Electric Company

1. Understand indications of gadolinium- versus iron-based blood pool contrast agents for MRA vascular examinations. 2. Understand strengths/limitations of different blood pool contrast agents in evaluation of peripheral vascular disease.

I. Background    a. Overiew of peripheral vascular disease and imaging techniques    b. Pharamacology of agents       i. Conventional extracellular fluid gadolinium-based agents       ii. Blood pool gadolinium-based: Gadofoveset Trisodium       iii. Blood pool iron-based: Ferumoxytol    c. Indications    d. Review of literature on safety and efficacy with respect to kidney function II. Technique   a. Administration   b. Bolus timing      i. Test bolus      ii. Bolus tracking      iii. Time resolved acquisition      iv. Dual bolus technique   c. MRA acquisition parameters III. Imaging appearance   a. Normal      i. Conventional MRA      ii. TRICKs      iii. High resolution steady state imaging      iv. Low resolution dynamic imaging   b. Proximal lower extremity disease   c. Distal lower extremity disease   d. Upper extremity disease IV. Advantages/Disadvantages   a. Safety profile   b. Bolus timing   c. Dose   d. Image resolution

http://abstract.rsna.org/uploads/2014/14019445/14019445_o5ey.pdf

Arasu, V, Gasper, W, Downey, R, Weinstein, S, Aslam, R, Hope, T, Comparison of Gadolinium- versus Iron-based MRA Blood Pool Contrast Agents used in Assessment of Peripheral Vascular Disease.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14019445.html